| CAS: | 794568-92-6 | ||
| 分子式: | C15H12ClF3N4O | ||
| 分子量: | 356.73 | ||
| 英文名称: |
| ||
| 用途: | BAY 73-6691 是一种有效且有选择性的脑渗透 PDE9A 抑制剂。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| B877342 | MACKLIN | BAY 73-6691 | ≥99% | 1625元/5mg; 2708元/10mg; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
储存：2-8℃ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| B3561 | Sigma-Aldrich | BAY 73-6691 | ≥98% (HPLC), powder | 2197.44元/5 MG; 8743.5元/25 MG; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 应用 BAY 73-6691 has been used as a phosphodiesterase 9 inhibitor in ischemic heart samples and in structural studies. It may be used as a PDE 9 inhibitor in neuroblastoma SH-SY5Y cells. 包装 5, 25 mg in glass bottle 生化/生理作用 BAY 73-6691 was characterized in vitro as the first potent and selective inhibitor of phosphodiesterase 9 (PDE9), which is currently under preclinical development for the treatment of Alzheimer′s disease. This compound selectively inhibits human (IC50 = 55 nM) and murine (IC50 = 100 nM) PDE9 activity in vitro and shows only moderate activity against other cyclic nucleotide-specific phosphodiesterases. BAY 73-6691 alone did not significantly increase basal cGMP levels. The PDE9 inhibitor significantly potentiated the cGMP signals generated by sGC activating compounds such as BAY 58-2667 or 5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine (BAY 41-2272) and induced leftward shifts of the corresponding concentration-response curves. The newly generated PDE9 reporter cell line show that BAY 73-6691 is able to efficiently penetrate cells and to inhibit intracellular PDE9 activity.† 特点和优势 This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
m.cnreagent.com
